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CASE PRESENTATION
A 49-year-old African-American female presented with
acute renal failure. Her serum creatinine had increased
from 0.8 to 2.8 mg/dl over 11 weeks. She had a 1-month
history of anorexia, 20 lb weight loss, nausea, and vague
abdominal discomfort. An outpatient evaluation included
a renal ultrasound and magnetic resonance imaging of the
abdomen, which were normal. Her past medical history
was significant for a 12-year history of hypertension. There
was no recent non-steroidal anti-inflammatory drug usage
or radiocontrast study. Her medications included losartan
100 mg daily, amlodipine 2.5 mg daily, hydrochlorothiazide
25 mg daily, and potassium chloride 20 mEq daily.
On physical examination, the patient appeared normal.
She was afebrile with a blood pressure of 168/98 mm Hg.
Her physical and neurologic exam was unremarkable.
There were no rashes, edema, or joint abnormalities.
Laboratory evaluation showed a total leukocyte count
of 7500/mm3 (normal range, 3500–11 000/mm3) with a
normal differential, hemoglobin 9.1 g/dl (normal range,
11.5–15.5 g/dl), reticulocytes 1.1% of total erythrocytes
(normal range, 0.5–1.5%), platelet count 419 000/mm3
(normal range, 150 000–450 000/mm3), serum sodium
140 mmol/l (normal range, 134–149 mmol/l), serum
potassium 4.0 mmol/l (normal range, 3.5–5.2 mmol/l),
serum chloride 103 mmol/l (normal range, 95–108 mmol/l),
serum bicarbonate 29 mmol/l (normal range, 23–30 mmol/
l), total serum calcium 8.7 mg/dl (2.2 mmol/l) (normal
range, 8.4–10.2 mg/dl (2.1–2.8 mmol/l)), serum albumin
3.2 g/dl (normal range, 3.5–5.0 g/dl), and cholesterol
216 mg/dl (normal range, 120–199 mg/dl). Liver function
tests were normal. Serologic evaluation revealed an
anti-nuclear antibody (ANA) titer of 1:2560 with a
homogenous staining pattern, and the presence of
perinuclear-staining anti-neutrophil cytoplasmic
antibodies (ANCAs), which were specific for
myeloperoxidase (MPO) (22 U/ml, normal o20 U/ml).
Complement C3 and C4 levels were normal. Cryoglobulins,
rheumatoid factor, hepatitis B antigen, and antibodies to
double-stranded DNA, extractable nuclear antigens
(Smith and ribonucleoprotein), histones, SS-A, SS-B,
proteinase 3, glomerular basement membrane (GBM), and
hepatitis C were not detectable. Urinalysis showed 3þ
protein and 4þ blood, with greater than 20 red blood
cells (normal less than 3) and white blood cells (normal
less than 5) per high-power field. There were granular
casts but no apparent cellular casts. There was 4470 mg of
protein (87% albumin, 7% polyclonal gamma globulin) in
a 24 h urine collection.
In the first week of hospitalization, her serum
creatinine rose to 3.5 mg/dl. A diagnostic renal biopsy was
performed.
RENAL BIOPSY FINDINGS
The renal biopsy contained up to 16 glomeruli for light
microscopic evaluation, of which four were globally sclerotic.
Cellular to fibrocellular crescents (Figure 1a) with frequent
disruption of Bowman’s capsules and segmental fibrinoid
necrosis of a few capillaries were identified in nine glomeruli.
One glomerulus contained a fibrous crescent. The GBM
showed marked thickening and subepithelial ‘spike’ forma-
tion without significant mesangial or endocapillary prolifera-
tion as seen with the Jones methenamine silver stain (Figure
1b). Diffuse and prominent interstitial inflammation con-
sisted of numerous plasma cells and lymphocytes and
demonstrated focal tubulitis. There was patchy interstitial
fibrosis and tubular atrophy involving up to 20% of the
biopsy. The sampled arteries and arterioles were without
evidence of vasculitis or significant sclerosis.
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Immunofluorescence (IF) microscopic evaluation of four
glomeruli revealed granular staining of primarily the capillary
walls and some mesangial areas for immunoglobulin (Ig)G
(3þ , Figure 1c), IgA (trace), IgM (trace), C3 (3þ ), C1q
(trace), and kappa (3þ ) and lambda light chains (1þ ).
There was no significant staining of the tubular basement
membranes or interstitium.
Electron microscopy of one glomerulus demonstrated
numerous immune-type electron-dense deposits in primarily
subepithelial locations (Figure 1d). There was basement
membrane material or ‘spike’ formation between these
electron-dense deposits. Significant deposits were not present
in mesangial or subendothelial regions. The podocyte foot
processes demonstrated extensive effacement. Endothelial
tubuloreticular inclusions or extraglomerular electron-dense
deposits were not identified.
Differential diagnosis
The diagnosis of membranous nephropathy (MN) can be
easily established in this patient. There is strong granular IF
staining of the capillary walls for IgG, C3, and kappa and
lambda light chains, which corresponds to the presence of
numerous subepithelial immune-type electron-dense depos-
its seen by electron microscopy. The additional IF staining for
IgA, IgM, and C1q satisfies a ‘full-house’ pattern that is most
suggestive of lupus nephritis. Although the presence of renal
disease and a positive ANA were the only major American
Rheumatism Association criteria for systemic lupus erythe-
matosus (SLE) in this patient, this is not an uncommon
occurrence in patients with lupus MN.1 Not infrequently,
MN is the first clinical manifestation of lupus. Particularly in
these instances, the distinction between idiopathic and lupus
MN can be difficult. Clues to the diagnosis of lupus MN
a
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Figure 1 | Renal biopsy findings. (a) Fibrocellular crescent occupies Bowman’s space with focal rupture of Bowman’s capsule. The glomerular
tufts uninvolved by crescent formation do not reveal significant mesangial or endocapillary hypercellularity. The interstitium shows a
prominent inflammatory mononuclear cell infiltrate (periodic acid-Schiff, high power). (b) The GBMs are thickened with diffuse subepithelial
‘spike’ formation, whereas the adjacent glomerular tufts lack significant mesangial or endocapillary hypercellularity (Jones methenamine silver,
high power). (c) IF microscopy demonstrates strong granular staining of the capillary walls and some mesangial areas for IgG. C3, and kappa
and lambda light chains revealed a similar glomerular IF staining pattern (data not shown). (d) Electron microscopy highlights several
subepithelial immune-type electron-dense deposits (arrowheads) with basement membrane material (or ‘spikes’) between the deposits.
The overlying podocyte foot processes show extensive effacement (original magnification  9800).
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include its appearance in young women in whom lupus is
more common than idiopathic MN, and a ‘full-house’ IF
staining pattern, the presence of tubuloreticular inclusions,
and/or coexisting immune deposits in various anatomic
locations outside the subepithelial space in the biopsy
specimen.
The main pathologic differential diagnosis includes diffuse
proliferative (class IV) and membranous (class V) lupus
nephritis or an ANCA-associated crescentic glomerulo-
nephritis superimposed on lupus MN. The absence of linear
GBM IF staining for IgG excludes anti-GBM disease. In
conjunction with the presence of ANCA and normal serum
complement levels, the absence of both significant sub-
endothelial or mesangial immune complex deposition, or
mesangial or endocapillary proliferation is most consistent
with a pauci-immune ANCA-associated crescentic glomer-
ulonephritis in the setting of lupus MN. Although the clinical
diagnosis of SLE is not firmly established, the ensuing
discussion will be based on a presumptive pathologic
diagnosis of lupus MN.
CLINICAL FOLLOW-UP
Owing to the clinical features of rapidly progressive
glomerulonephritis, the patient was empirically given 1 g
of IV methylprednisolone, which was repeated for a total
of three daily doses when the initial histological diagnosis of
crescentic glomerulonephritis was obtained. She was also
given 1.6 g of IV cyclophosphamide (0.8 g/m2), which was
well tolerated. Oral iron and darbepoetin alfa were started for
anemia. Her hypertension was difficult to control initially, yet
later in the hospital course was controlled with losartan and
verapamil, which she continued as an outpatient. On hospital
day 11, her serum creatinine was 2.2 mg/dl (194 mmol/l),
which further decreased to 1.3 mg/dl (146 mmol/l) 2 weeks
later.
Because of persistently active urinary sediment and a
transient rise in serum creatinine to 2.4 mg/dl (270 mmol/l) 2
months after hospitalization, she received escalating monthly
doses of intravenous cyclophosphamide to a maximum of
2.0 g (1.0 g/m2), together with 1 g intravenous methylpredni-
solone for a total of six doses, after which she was maintained
on 3.0 g/d mycophenolate mofetil. Three months after her
hospitalization, her serum creatinine was 1.0 mg/dl (88 mmol/
l) and urinary protein/creatinine 1.0 (normal 0–0.15). For the
ensuing year, she did well with repeated serum creatinine
measurements between 1.0–1.1 mg/dl, urinary protein/crea-
tinine less than 1.7, and resolution of anemia. At the 1-year
period, her ANA titer was 1:640 and ANCA was undetectable.
DISCUSSION
Crescentic glomerulonephritis represents a severe form of
glomerular injury that is characterized by disruption of the
GBM leading to cellular proliferation within Bowman’s space,
often accompanied by fibrinoid necrosis. Crescentic glomer-
ulonephritis is classified into three main immunopathologic
categories: (1) anti-GBM disease; (2) immune complex-mediated
glomerulonephritis; and (3) pauci-immune (ANCA-asso-
ciated) glomerulonephritis. In the setting of SLE, crescentic
glomerulonephritis is usually associated with prominent
immune complex deposition in subendothelial regions,
which often correlates with the histologic finding of
endocapillary proliferation, ‘wire-loop’ deposits, or cellular
crescent formation. However, in the absence of significant
mesangial and subendothelial immune complex deposition
and glomerular endocapillary hypercellularity, a pauci-
immune (ANCA-associated) glomerular injury process
should be a diagnostic consideration as the underlying cause
of the crescentic glomerulonephritis.
Lupus glomerular lesions are categorized according to the
2003 International Society of Nephrology/Renal Pathology
Society revised lupus nephritis classification. In addition,
renal biopsies of SLE patients have revealed a spectrum of
diseases that are not considered within the lupus nephritis
classification scheme, including thin GBM disease, focal
segmental glomerulosclerosis, amyloidosis, IgM nephropathy,
IgA nephropathy, sarcoidosis, and hypertensive nephrosclero-
sis.2–5 Lupus nephritis occurring concurrently with another
renal injury process has been reported with minimal change
disease (podocytopathy).6,7 Of particular relevance to the
current report, there are five cases (Table 1) of lupus nephritis
with pauci-immune crescentic glomerulonephritis in the
literature of which two cases demonstrated class V lupus
MN.8–10 Schwartz et al.11 and Ferrario et al.12 report an
additional 13 SLE cases with similar histopathologic findings,
although ANCA serologies were not available and there was
limited IF and no electron microscopy was performed in the
latter study.
Analogous to the notion that not all ANAs are equal,
ANCAs also represent a heterogenous group of antibodies
with variable degrees of specificity or avidity, as illustrated by
Table 1 | Renal biopsies of lupus nephritis and pauci-immune GN
Case Age (years)/sex Renal biopsy findings ANCA (ELISA) Clinical outcome Reference
1 17/F Class III LN+focal necrotizing GN Negative Methylprednisone+IV CYC with good recovery Akhtar et al.8
2 40/F Class IV LN+crescentic GN Negative Prednisone+CYC; follow-up N/A Akhtar et al.8
3 55/M Class V LN+crescentic GN pANCA (ND) Died 1.5 months after biopsy Marshall et al.9
4 37/F Class V LN+crescentic GN pANCA (MPO) Prednisone+IV CYC with creatinine of 1.3 mg/dl Marshall et al.9
5 50/F Class III LN+crescentic GN pANCA (MPO) Prednisone+IV CYC with good recovery Masani et al.10
6 49/F Class V LN+crescentic GN pANCA (MPO) Methylprednisolone+IV CYC with good recovery Current case
ANCA, anti-neutrophil cytoplasmic antibody; CYC, cyclophosphamide; ELISA, enzyme linked immunosorbent assay; F, female; GN, glomerulonephritis; LN, lupus nephritis;
M, male; MPO, myeloperoxidase; N/A, not available; ND, not done; pANCA, perinuclear ANCA.
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their different targets, which include MPO, proteinase 3,
lysozyme, lactoferrin, cathepsin G, and elastase to name a
few.13 Just like with the suggestions that anti-double-stranded
DNA antibodies may play a pathogenic role in lupus
nephritis, recent data implicate ANCA as an important
pathogenic factor. Xiao et al.14 demonstrated that the
administration of IgG antibodies specific for MPO alone in
RAG2-knockout mice could lead to vasculitis and crescentic
glomerulonephritis. One case of transplacental transmission
of MPO-ANCA causing rapidly progressive glomerulo-
nephritis in a newborn has been reported, although this
was not confirmed with a renal biopsy.15 The proposed
mechanism of injury by ANCAs begins with the activation of
neutrophils and monocytes, which leads to formation of
reactive oxygen species and subsequent damage to the
endothelial cells and basement membranes that can result
in rupture and subsequent glomerular crescent formation.
Approximately 15–20% of SLE patients have detectable
ANCA (Table 2). The majority of these have a perinuclear
staining pattern by indirect IF, which typically is attributable
to reactivity to either MPO (as in our patient) or lactoferrin.
Cytoplasmic ANCA staining and/or reactivity to proteinase 3
are seen in a minority of patients (approximately 2%). A
number of studies have attempted to correlate ANCA
seropositivity with various clinical manifestations of SLE
including renal disease with mixed results (reviewed by Sen
and Isenberg13). Thus, there are studies that show no
association of anti-MPO or anti-lactoferrin ANCA with
lupus nephritis16–21 and those that do suggest the two are
linked22–25 (Table 2). In these studies, the descriptions of
renal histopathologic findings were limited. As such, overall it
is difficult to arrive at generalizations regarding ANCA in
lupus nephritis.
There have been a few studies that have focused
specifically on the histopathologic features of lupus nephritis.
Using the revised 2003 International Society of Nephrology/
Renal Pathology Society lupus classification, Hill et al.26
found that diffuse segmental proliferative (class IV-S) lupus
nephritis had fewer immune deposits and more fibrinoid
necrosis when compared to diffuse global proliferative (class
IV-G) lupus nephritis, which behaved as an immune
complex-mediated disease process. Mittal et al.27 observed
similar findings, but they did not find the difference between
classes IV-G and IV-S lesions to be statistically significant.
Hill et al.26 suggested the possibility that an alternate
pathogenic mechanism, such as an ANCA-mediated process,
may be the cause of the class IV-S lesions, but unfortunately
ANCA titers were not available in either study. It does seem
clear that a limited subset of patients with lupus nephritis can
have concomitant pauci-immune crescentic glomerulo-
nephritis associated with ANCA (Table 1). Although
ANCA-related vasculitis is autoimmune in nature, in this
instance whether it is an extension of the underlying
autoimmune disease in SLE, or alternatively is a separate
phenomenon, remains to be established.
Lupus MN occurs in up to 20% of lupus nephritis
patients.1 The pathogenesis of both idiopathic and lupus MN
remains unclear. In MN, there is the uniform presence of
subepithelial immune deposits and complement components
together with ultrastructural evidence for podocyte damage.
The latter can account for proteinuria, given the key role for
podocytes to maintain the normal glomerular permselectivity
barrier to protein passage. The weight of experimental
evidence supports that complement activation results in C5b-
9-mediated injury of podocytes, but no chemoattractant-
mediated influx of inflammatory cells owing to the separa-
tion of the subepithelial and vascular spaces by the GBM.28
Work in the Heymann nephritis model in rats has shown that
antibodies to podocyte antigens can form subepithelial
immune complexes in situ. Recently, this mechanism has
been shown to be operative in neonatal MN owing to
passively transferred maternal antibodies to podocyte neutral
endopeptidase.29 This is an uncommon form of MN, and
other podocyte target antigens have been elusive. It is likely
that autoantibodies binding to intrinsic podocyte antigens is
not the exclusive mechanism for subepithelial immune
Table 2 | Serologic detection of ANCA in SLE patients with lupus nephritis
Study
Number of
patients pANCA+ (%) MPO+ (%) LF+ (%) Conclusions
Lee et al.16 79 20.2 5.1 39.2 No correlation with anti-LF Abs and lupus nephritis.
Among class IV lesions, 3 of 4 patients with anti-LF Abs
and 1 of 8 without anti-LF-Abs contained crescents
Sinico et al.17 70 ND ND 15–20 No correlation with anti-LF Abs and lupus nephritis
Schnabel et al.18 120 25 0 10 No correlation with ANCA and lupus nephritis
Spronk et al.19 84 9.5 8.3 15.5 No correlation with ANCA and lupus nephritis
Nishiya et al.20 31 42 16.1 32.2 No correlation with ANCA and lupus nephritis or proteinuria
Zhao et al.22 95 18.9 0 8.4 62% of all samples (86% of ANCA+ samples) recognized
cathepsin G. Anti-cathepsin G Abs
but not anti-LF Abs correlate with lupus nephritis
Chin et al.23 51 31.4 2.4 30.2 Positive ANCA associated with lupus nephritis
Manolova et al.21 55 27.3 10.9 18.2 No correlation with ANCA and lupus nephritis
Pradhan et al.24 59 33.9 20.3 16.9 ANCA titers correlated and were higher in patients
with lupus nephritis
Caccavo et al.25 97 ND ND 54.6 Anti-LF Ab titers correlate with lupus nephritis
Abs, antibodies; ANCA, anti-neutrophil cytoplasmic antibody; LF, lactoferrin; MPO, myeloperoxidase; ND, not done; pANCA, perinuclear ANCA; SLE, systemic lupus
erythematosus.
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deposit formation in idiopathic or lupus MN, with other
possible mechanisms including antibody binding to extrinsic
antigens in the subepithelial region and extrinsic immune
complexes traversing the GBM. Given the diversity of
autoantibodies in lupus, it seems likely that any or all of
these could be operative in lupus MN.
The pathologic distinction between coexisting diffuse
proliferative lupus nephritis and lupus MN from a pauci-
immune, ANCA-associated crescentic glomerulonephritis on a
background of lupus MN can be problematic. One could argue
the distinction is not crucial, given that the current therapeutic
regimens available for both consist of intensive, but non-
specific immunosuppression. Once the clinical diagnosis of
rapidly progressive glomerulonephritis is made, treatment
with high-dose pulse intravenous corticosteroids is widely
used and can be considered standard-of-care. Thereafter,
induction therapy with oral or intravenous cyclophosphamide
is often used. Intravenous cyclophosphamide has the advan-
tage of a lower cumulative dose and the relative success of
prophylaxis against hemorrhagic cystitis; this regimen has been
shown to be effective in diffuse proliferative lupus nephritis,
whereas only suggested to be effective in lupus MN and in
ANCA-associated diseases.30,31 The clear role for daily oral
cyclophosphamide in the latter has been proven, and remains
the mainstay of therapy until supplanted by more directed
forms of treatment.32 Our use of ‘pulse’ intravenous cyclopho-
sphamide was a conscious decision based upon the presump-
tion that it is active against both ANCA-associated
glomerulonephritis and lupus MN, as well as it is generally
being well-tolerated. Thereafter, the use of daily oral
mycophenolate mofetil for maintenance therapy was based
on its effectiveness in diffuse proliferative lupus nephritis and
that it is also well-tolerated, but with no proof of efficacy for
the two diseases present. Despite the potential pathogenic role
of ANCAs and ANAs, the precise role for plasmapheresis in
patients with lupus nephritis or ANCA-associated glomerulo-
nephritis remains to be established. The most convincing
evidence for a possible role for plasma exchange is in those
patients with ANCA-associated glomerulonephritis with severe
enough disease to require renal replacement therapy.33 Our
patient did not receive plasma exchange, and she had a
dramatic response to pulse intravenous corticosteroids and
cyclophosphamide, as her serum creatinine went from 3.5 to
1.3 mg/dl in 3 weeks. Thereafter, she did well with 6 months of
this therapy followed by 6 months of daily oral mycophenolate
mofetil. Unfortunately, we cannot make generalizations to use
this type of therapeutic regimen in patients with a similar
presentation, given the anecdotal nature of this case. Proof
continues to await definitive clinical studies on these
established and newer therapies.
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